• KOL
    • Testicular Volume
    • Abraham T K Cockett
    • ABRAHAM T K COCKETT: Influence Statistics

      ABRAHAM T K COCKETT

      ABRAHAM T K COCKETT

      Departments of Pathology (JER, MJO, ZY, JFM, LC, RDR, LLW), Urology (INF, EMM, ATKC), and Biostatistics (CC), University of Rochester, Rochester, New York, USA | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      ABRAHAM T K COCKETT:Expert Impact

      Concepts for whichABRAHAM T K COCKETThas direct influence:Testicular volume,Prostate cancer,Neuroendocrine differentiation,Contralateral testes,Dna cytometry,Bladder cancer,Detrusor instability,Bladder carcinoma.

      ABRAHAM T K COCKETT:KOL impact

      Concepts related to the work of other authors for whichfor which ABRAHAM T K COCKETT has influence:Prostate cancer,Benign prostatic hyperplasia,Transurethral resection,Urinary tract,Specific antigen,Quality life,Testicular torsion.

      KOL Resume for ABRAHAM T K COCKETT

      Year
      1998

      Departments of Pathology (JER, MJO, ZY, JFM, LC, RDR, LLW), Urology (INF, EMM, ATKC), and Biostatistics (CC), University of Rochester, Rochester, New York, USA

      Department of Urology, Box 656, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642

      1997

      Department of Urology, University of Rochester School of Medicine, Rochester, New York,USA

      1996

      From the Departments of Urology, Pathology, and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA

      Department of Medicine, University of California and the San Diego Veterans Affairs Medical Center, La Jolla, California U.S.A.

      1995

      From the Medical Practices Evaluation Center, Massachusetts General Hospital and Division of Urology, Brigham and Women's Hospital, Boston, Massachusetts, Department of Urology, University of Rochester School of Medicine, Rochester, New York, and Departments of Epidemiology and Biostatistics, Merck Research Laboratories, Blue Bell, Pennsylvania The Benign Prostatic Hyperplasia Treatment Outcomes Study Group. Accepted for publication July 8, 1994. Supported in part by Grants HS 06336, 06689 and 08397 from the Agency for Health Care Policy and Research, and Merck Research Laboratories.

      Department of Urology, University of Lund, Malmö General Hospital, Sweden

      1994

      Departments of Urology, Pathology, and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA

      Department of Urology, University of Lund, Malmo General Hospital, Mälmo, Sweden

      1993

      Johns Hopkins School of Medicine, Baltimore, Maryland

      CanAg Diagnostics AB, Gothenburg, Sweden

      University of Iowa College of Medicine, Iowa, City, Iowa

      Urology Service, Walter Reed Army Medical Center, Washington, D. C.

      From the Medical Practices Evaluation Center, Massachusetts

      1992

      University of Rochester, Rochester, New York

      American Urological Association, Baltimore, Maryland

      Department of Urology, Strong Memorial Hospital, 601 Elm wood Avenue, Box 656, Rochester, NY 14642

      1991

      Department of Radiation Oncology, University ofRochester Cancer Center, Strong Memorial Hospital, Rochester, USA

      1990

      Urology Department, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 656, 14 642, Rochester, NY, USA

      1989

      Urology Department, University of Rochester School of Medicine, Rochester, New York, USA

      1988

      From the Department of Urology, University of Rochester School of Medicine, Rochester, New York

      1987

      Department of Urology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 656, 14642, Rochester, New York, USA

      1986

      Departments of Urology and Pathology, University of Rochester School of Medicine and Dentistry, Rochester, New York

      1985

      From the Departments of Urology and Pathology, University of Rochester School of Medicine and Dentistry, Rochester, New York

      1982

      From the Departments of Surgery (Division of Urology), Pathology, Radiology, and Radiation Therapy, The University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

      1981

      From the Departments of Radiology and Pathology, and Divisions of Urology and Radiation Therapy, The University of Rochester School of Medicine and Dentistry, Rochester, New York USA

      1980

      From the Department of Radiology and Division of Urology, The University of Rochester School of Medicine and Dentistry, Rochester, New York

      1979

      From the Department of Radiology and Division of Urology, University of Rochester, School of Medicine and Dentistry, Rochester, New York, USA

      1974

      From the Department of Radiology, Division of Diagnostic Radiology, and Department of Surgery, Division of Urology, University of Rochester, School of Medicine and Dentistry, Strong Memorial Hospital, Rochester, New York

      Sign-in to see all concepts, it's free!
      Sample of concepts for which ABRAHAM T K COCKETT is among the top experts in the world.
      Concept World rank
      hybridization irrigation #1
      antitumor mbt2 #1
      cerbb2 neuroendocrine cells #1
      prostatic malignancy background #1
      pathological contralateral testes #1
      chemotherapy female interleukin2 #1
      contralateral testes fertility #1
      sensitivity chromosome #1
      bladder tumor dose #1
      controlled bladder distension #1
      bso dose #1
      il2 bladder #1
      89 infertile #1
      bso sulfoximine carcinoma #1
      bladder thirtyfour patients #1
      porcine sensitized #1
      prepubertal rats duration #1
      attenuated irradiation immunotherapy #1
      varicoceles operative repair #1
      renal subcapsular area #1
      cisplatin bun concentration #1
      improvement testicular volume #1
      implantability growth #1
      sequential scans bony #1
      biopsies eosinophilia #1
      egfr prostatic #1
      hesw influence #1
      increase testicular volume #1
      specific histologic degeneration #1
      mbt2 c3h #1
      gas insufflation technique #1
      pathway regulating cells #1
      testes subjected #1
      hesw control #1
      dna cytometry specificity #1
      androgen serotonin #1
      infiltrative bladder #1
      intravenous contrast fusion #1
      virtually prostate #1
      eswl population #1
      9 aberrations fluorescence #1
      c3h mice pretreatment #1
      skin subcapsular #1
      clinical arms bcg #1
      immunotherapy new methodology #1
      Sign-in to see all concepts, it's free!

      Prominent publications by ABRAHAM T K COCKETT

      KOL-Index: 12173

      Prostate specific antigen (PSA) in serum has recently been shown to occur in complex with alpha 1-antichymotrypsin and as an approximately 30 kDa. noncomplexed molecular form. We characterized PSA by 3 different assays in samples from 144 patients with benign prostatic hyperplasia (BPH) and 121 with carcinoma of the prostate. One of these noncompetitive assays measured total PSA by detecting PSA complexed to serine proteinase inhibitors and the noncomplexed molecular form, a second ...

      Known for Prostate Cancer | Psa Complex | Alpha 1antichymotrypsin | Specific Antigen | Tumor Diagnosis
      KOL-Index: 12109

      OBJECTIVES: Neuroendocrine differentiation in carcinoma of the prostate is characterized by the expression of neuroendocrine cell products such as chromogranin A (CgA). We studied serum levels and tissue staining for CgA in prostate cancer to assess their clinical value.

      METHODS: In 82 patients with prostate cancer, serum specimens were obtained at diagnosis and studied by both CgA and prostate-specific antigen (PSA) immunoassays. In 43 additional patients with prostate cancer, ...

      Known for Serum Cga | Prostate Cancer | Tumor Chromogranin | Neuroendocrine Marker | Specific Antigen
      KOL-Index: 11747

      BACKGROUND: Prostate specific antigen (PSA) is a zymogen of a 33-kilodalton (kD) serine proteinase with extensive similarity to glandular kallikreins. The mechanism responsible for converting the zymogen into active proteinase has not been defined, but active PSA may be irreversibly inactivated in vitro by two of the major proteinase inhibitors in blood: alpha 1-antichymotrypsin and alpha 2-macroglobulin.

      METHODS: Procedures have been designed to characterize the different molecular ...

      Known for Prostate Specific Antigen | Psa Complex | Neoplasm Biomarkers | Proteinase Inhibitor | Molecular Forms
      KOL-Index: 10494

      OBJECTIVES: To determine the sensitivity and specificity of combining fluorescence in situ hybridization (FISH) measurement of chromosome 9 and DNA cytometry of bladder irrigation specimens in the detection of bladder cancer.

      METHODS: Bladder irrigation specimens were obtained from 37 normal control patients and 317 bladder cancer patients during cystoscopic examinations. Bladder cancer patients were sampled in the absence of observable tumor (256 specimens) and concurrently with tumor ...

      Known for Irrigation Specimens | Dna Cytometry | Chromosome 9 | Bladder Cancer | Situ Hybridization
      KOL-Index: 10245

      BACKGROUND: The prostatic neuroendocrine cell is a regulatory cell that produces serotonin and peptide hormones. This cell is part of a more widely dispersed diffuse neuroendocrine regulatory system known as the APUD system. Focal neuroendocrine differentiation is seen in virtually all prostate carcinomas to one degree or another. Specific malignancies that are purely neuroendocrine include small cell carcinoma and carcinoid/carcinoid-like tumors. A variety of studies suggest a possible ...

      Known for Neuroendocrine Differentiation | Prostate Carcinoma | Prostatic Malignancy | Prognostic Significance | Therapeutic Implications
      KOL-Index: 10108

      Neuroendocrine (NE) cells containing neurosecretory granules, rich in various peptide hormones and biogenic amines such as serotonin (5-HT), are components of the human prostate epithelium. The NE cells probably subserve a paracrine or local regulatory role in both prostatic growth and differentiation as well as the exocrine secretory process. Neuroendocrine cells may be involved in the etiology of benign prostatic hyperplasia (BPH). In this study the number of NE cells in areas of BPH ...

      Known for Prostatic Hyperplasia | Neuroendocrine Cells | Bph Normal Tissue | Normal Prostate | 5 Ht
      KOL-Index: 9221

      OBJECTIVE: We recently demonstrated that parathyroid hormone-related protein (PTHrP) is widely expressed by human prostate cancer tissue, suggesting that PTHrP might be involved in the growth and development of prostate cancer. To study this further, the production of PTHrP and its biologic effect were investigated using human prostate cancer cell lines.

      METHODS: The cell lines used were one androgen-dependent cell line, LNCaP, and two androgen-independent cell lines, PC-3 and DU-145. ...

      Known for Cell Lines | Prostate Cancer | Parathyroid Hormone | Protein Pthrp | Autocrine Growth
      KOL-Index: 9182

      Endocrine-paracrine (neuroendocrine, amine precursor uptake and decarboxylation [APUD]) cells of the prostato-urethral region are serotonin and peptide containing regulatory cells, which are part of a dispersed neuroendocrine regulatory system also known as the APUD system. These cells most likely regulate growth and differentiation, as well as the secretory functions of the prostate. Prostatic carcinoma exhibits neuroendocrine differentiation in 3 forms: 1) small cell neuroendocrine ...

      Known for Neuroendocrine Differentiation | Prostatic Carcinoma | Carcinoidlike Tumors | Small Cell | Prognostic Significance
      KOL-Index: 9130

      In previous studies the severity of symptoms of prostatism in men with benign prostatic hyperplasia have not correlated well with prostate size, degree of bladder trabeculation, uroflowmetry or post-void residual volume. As part of a prospective cohort study of benign prostatic hyperplasia treatment effectiveness in 4 university-based urology practices, we correlated symptom severity and these commonly used measures of disease severity. Symptom severity was quantified using the American ...

      Known for Symptom Severity | Benign Prostatic Hyperplasia | Bladder Trabeculation | Prostate Size | 6 Months
      KOL-Index: 8282

      OBJECTIVES: To discover whether the proteolytic activity of prostate-specific antigen (PSA) affects the structure and function of parathyroid hormone-related protein (PTHrP), as both are abundant components of human seminal plasma.

      METHODS: The ability of PTHrP to act as a substrate was studied by incubating a synthetic polypeptide, consisting of 34 amino acid residues of the amino-terminal domain of PTHrP, with purified PSA. The incubate was then analyzed by sodium dodecyl ...

      Known for Parathyroid Hormone | Specific Antigen | Proteolytic Activity | Substrate Psa | Protein Pthrp
      KOL-Index: 8255

      DNA slit-scan flow cytometry was used to analyze 150 bladder irrigation specimens from 83 patients. Specimens were categorized into groups based on cystoscopy, histology, and cytopathology. Cells were stained for DNA with propidium iodide using a whole cell protocol. Non-specific fluorescence in the cytoplasm of some urothelial cells together with differential DNA staining of cell types in certain specimens was noted. DNA frequency distributions were analyzed using a semi-automated ...

      Known for Urothelial Cells | Irrigation Specimens | Flow Cytometry | Cell Dna | Urinary Bladder
      KOL-Index: 8226

      OBJECTIVES: Parathyroid hormone-related protein (PTHrP) is a primary factor in the pathogenesis of malignancy-associated hypercalcemia. By alternative splicing, the human PTHrP gene can generate three different species of mRNA that encode three initial translational isoforms of 139, 173, and 141 amino acids. We recently reported that PTHrP was present in normal prostatic neuroendocrine cells and was overexpressed in prostate cancer tissue as demonstrated by immunostaining. This study was ...

      Known for Prostate Cancer | Parathyroid Hormone | Messenger Tumor Cells | Pthrp Expression | Pc3 Du145
      KOL-Index: 8141

      DL-Buthionine-(S, R)-sulfoximine (BSO), a glutathione-depleting agent, was found to diminish the nephrotoxic effect of cisplatin (cis-diamminedichloroplatinum). Pretreatment of rats with BSO (4 mmol/kg s. c.) 2 h prior to cisplatin, either as a single dose of 5 mg/kg or at a daily dose of 2.5 mg/kg for 3 consecutive days, resulted in diminished elevations of plasma BUN concentration and decreased cisplatin-induced inhibition of renal γ-glutamylcysteine synthetase and γ-glutamyl ...

      Known for Rats Bso | Buthionine Sulfoximine | Antitumor Activity | 4 Mmol | Induced Nephrotoxicity
      KOL-Index: 8136

      Simultaneous presentation of transitional cell carcinoma of the bladder and adenocarcinoma of the prostate is not uncommon. Twenty-two patients were diagnosed as having simultaneous or concurrent presentation of prostate and bladder carcinomas between January 1970 and July 1986. The overall five-year survival was 40 percent, with patients presenting with prostate cancer doing better (50%) than those with bladder cancer (32%). Retrospective review of these cases suggests that primary ...

      Known for Bladder Cancer | Transitional Cell | Adenocarcinoma Prostate | Radiation Therapy | Retrospective Review
      KOL-Index: 7952

      OBJECTIVES: A subpopulation of prostate neuroendocrine (NE) cells contain calcitonin (CT). It has been postulated that CT-producing cells in the prostate account for the high CT level in the semen, and may be involved in the regulation of other epithelial cells via a paracrine mechanism. The presence of CT binding sites in the plasma membrane fraction of prostate tissue has been demonstrated by radioligand binding assay. In the present study, we investigated the CT receptor gene ...

      Known for Calcitonin Receptor | Mrna Expression | Situ Hybridization | Prostate Tissue | Epithelial Cells

      Key People For Testicular Volume

      Top KOLs in the world
      #1
      Eberhard Nieschlag
      male infertility macaca fascicularis stimulating hormone
      #2
      Hiroshi Takihara
      male infertility interstitial fibrosis sperm motility
      #3
      Niels Erik Skakkebaek
      germ cell semen quality testicular cancer
      #4
      ALEKSANDER GIWERCMAN
      semen quality testicular cancer germ cell
      #5
      Hermann M Behre
      serum levels male contraception gnrh antagonist
      #6
      Abraham Timothy K Cockett
      sperm motility seminal plasma decompression sickness

      Departments of Pathology (JER, MJO, ZY, JFM, LC, RDR, LLW), Urology (INF, EMM, ATKC), and Biostatistics (CC), University of Rochester, Rochester, New York, USA | Department of Urology, Box 656, University of Rochester Medical Center, 601 Elmwood Ave.

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.